As customer success stories from AI accelerator start ups starting to proliferate, and traction starting to ramp up, it is starting to become clear which ML workloads are most amenable to domain specific architectures, and which market sectors are most likely to adopt novel AI acceleration technologies.
With one company still retaining the majority of market share in the datacenter, and the edge currently a complete wilderness, it might still be a difficult time to launch a new accelerator company. But opportunities for capturing market share across the cloud-edge continuum definitely exist! In the world of HPC, certain ML and non-ML scientific workloads have seen extraordinary, demonstrable speed ups on novel ML systems architectures, and the scientific community only sees demand for acceleration of these types of workloads growing. At the edge some AI chip companies are already shipping in volume, while new applications emerge continuously.
This panel will look at what it takes to make it in the AIHW game, what might shift the balance of power in the datacenter, and how companies can find a niche at the edge.
Brett is a co-founder of Arete (formed in 2000) and is based in the firm's London office. He focuses on the global semiconductor component sector. Brett is a regular public speaker at industry events and after 17 years looking at the sector, has a wealth of experience to draw on. Prior to Arete, Brett spent two years at Goldman Sachs in an equity analyst role, specialising in European technology following three years with Ericsson UK, working in business development, covering all aspects of wireline and wireless telecom infrastructure.
Gayathri is currently Partner at Hitachi Ventures. Prior to that, she was with Micron Ventures, actively investing in startups that apply AI to solve critical problems in the areas of Manufacturing, Healthcare and Automotive. She brings over 20 years of multi-disciplinary experience across product management, product marketing, corporate strategy, M&A and venture investments in large Fortune 500 companies such as Dell and Corning and in startups. She has also worked as an early stage investor at Earlybird Venture Capital, a premier European venture capital fund based in Germany. She has a Masters in EE from The Ohio State University and MBA from INSEAD in France. She is also a Kauffman Fellow - Class 16.
As AI makes its way into healthcare and medical applications, the role of hardware accelerators in the successful deployment of such large AI models becomes more and more important. Nowadays large language models, such as GPT-3 and T5, offer unprecedented opportunities to solve challenging healthcare business problems like drug discovery, medical term mapping and insight generation from electronic health records. However, efficient and cost effective training, as well as deployment and maintenance of such models in production remains a challenge for healthcare industry. This presentation will review a few open challenges and opportunities in the healthcare industry and the benefits that AI hardware innovation may bring to the ML utilization.
Hooman Sedghamiz is Director of AI & ML at Bayer. He has lead algorithm development and generated valuable insights to improve medical products ranging from implantable, wearable medical and imaging devices to bioinformatics and pharmaceutical products for a variety of multinational medical companies.
He has lead projects, data science teams and developed algorithms for closed loop active medical implants (e.g. Pacemakers, cochlear and retinal implants) as well as advanced computational biology to study the time evolution of cellular networks associated with cancer , depression and other illnesses.
His experience in healthcare also extends to image processing for Computer Tomography (CT), iX-Ray (Interventional X-Ray) as well as signal processing of physiological signals such as ECG, EMG, EEG and ACC.
Recently, his team has been working on cutting edge natural language processing and developed cutting edge models to address the healthcare challenges dealing with textual data.
Nadia Spiccia is an associate in Kirkland’s Intellectual Property Litigation Practice Group in London. Nadia’s practice focuses on complex cross border and multijurisdictional life sciences patent disputes requiring significant coordination across multiple forums at both first instance and on appeal. With over 12 years’ experience supporting global pharma/biopharma and a background in chemistry, Nadia leverages her legal and technical experience to provide strategic counselling. Prior to joining Kirkland, Nadia was Head of Patent Litigation - ex NA at Sandoz responsible for the launch and litigation of Sandoz’s small molecule and biosimilars worldwide apart from North America. Prior to this Nadia was Head of Legal and Company Secretary - ANZ for Mylan (now Viatris). Nadia was recognised by Managing IP as a Notable Practitioner in the 2021 edition of its IP Stars guide and as a Corporate IP Star – Europe in the 2019-2020 editions. She was also named to the list of Leading In-House Intellectual Property & TMT Lawyers – Australia by Doyle’s Guide in the 2019-2020 editions.
One of the biggest challenges in the US is managing the cost of healthcare. Although we have high healthcare costs in the US, our life expectancy is still average. In this talk we will look at some of the core causes of healthcare costs and what modern AI hardware can do to lower these costs. We will see that faster and bigger GPUs alone will not save us. We need detailed models to across a wide swath of our communities and perform early interventions. We need accurate models of our world and the ability to simulate the impact of policy changes to overall healthcare costs. We need new MIMD hardware with cores and memory architecture that keep cores fed with the right data.
Dan is a distinguished engineer in AI working on innovative database architectures including document and graph databases. He has a strong background in semantics, ontologies, NLP and search. He is a hands-on architect and like to build his own pilot applications using new technologies. Dan started the NoSQL Now! Conference (now called the Database Now! Conferences). He also co-authored the book Making Sense of NoSQL, one of the highest rated books on Amazon on the topic of NoSQL. Dan worked at Bell Labs as a VLSI circuit designer where he worked with Brian Kernighan (of K&R C). Dan also worked with Steve Jobs at NeXT Computer.
Chad is a principal in the firm’s San Diego office and is the go-to patent litigator for numerous multinational life sciences companies — including Gilead, GSK, iCeutica, Iroko, Coherus Biosciences and Dainippon Sumitomo Pharma — whose marquee products deliver billions of dollars in annual revenues. He draws on his litigation experience, extensive network of scientific and business experts, and detailed knowledge of his clients’ companies to provide strategic legal counsel on a wide range of business matters. With extensive global experience, including serving as lead attorney in complex patent proceedings, trials and appeals across Asia, Europe, North America, and Australia, Chad has proven to be a results-focused, hands-on leader known for assembling and managing effective, collaborative teams across multiple time zones, firms, and languages.
Harshit Khaitan is the Director of AI Accelerator at Meta where he leads building AI Accelerators for Reality labs products. Prior to Meta, he was technical lead and co-founder for the Edge Machine learning accelerators at Google, responsible for MLA in Google Pixel 4 (Neural Core) and Pixel 6 (Google Tensor SoC). He has also held individual and technical leadership positions at Google’s first Cloud TPU, Nvidia Tegra SoCs and Nvidia GPUs. He has 10+ US and international patents in On-device AI acceleration. He has a Master’s degree in Computer Engineering from North Carolina State University and a Bachelor’s degree in Electrical Engineering from Manipal Institute of Technology, India.
Sharada has spent the last decade building global IP strategies to launch biosimilars. She started her career in the US with the patent litigation group at Proskauer Rose, participating in several ITC litigations in addition to her district court docket. In 2012, she moved to Boehringer Ingelheim to begin her career in the then-new and exciting biosimilars market. There she helped build strategies for most of the first wave biosimilar, in addition to advising her client how to prepare for global biosimilar litigation. More recently, she leads the biosimilar IP team at Sandoz, a global leader in biosimilars, for the next wave of launches.